tirzepatide surmount 3 study after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase trial Lilly Shows Tirzepatide Superiority in – tirzepatide being discontinued Tirzepatide after

Many patients remain at the 2.5 mg weekly injection dose because they tolerate it well, but the clinical trials that showed significant weight loss used 5 mg and 10 mg weekly doses

That is a fundamental limitation

Novo will, however, keep patent protection for semaglutide in Europe and Japan until 2033, and in the US until 2032

Given this pattern in weight loss following treatment with an AOM, anti-obesity therapy should be conceptualized as initiating weight loss followed by establishing a new weight plateau and assisting in maintaining this weight in the long term [9, 11]

Therefore its important to talk to your doctor before taking this peptide or any other medication or supplement for health related issues

The manufacturer, despite being the cause of the supply failure, still owns the patent rights